| Description |
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity[1].
|
| Related Catalog |
|
| In Vitro |
Ontorpacept (0.001-1000 nmol/L；2 h) 在急性髓性白血病，骨髓增生异常综合征，多发性骨髓瘤，B 细胞急性淋巴细胞白血病和 T 细胞急性淋巴细胞白血病患者的肿瘤细胞样本中，剂量依赖性地增加肿瘤细胞的巨噬细胞吞噬作用，平均 EC50 为 10 nmol/L[1]。
|
| In Vivo |
Ontorpacept (8 mg/kg；腹腔注射，每周 3 次，共 4 周) 在 SCID 小鼠急性髓性白血病异种移植模型中具有抗肿瘤活性[1]。 Animal Model: NOD.SCID mice with AML cell transplants[1] Dosage: 8 mg/kg Administration: Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks Result: Significantly reduced the tumor growth in bone marrow and spleen.
|
| References |
[1]. Petrova PS, et al. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079.
|
